Full digitalization of production processes is at the heart of DataHow’s vision … Our collaboration with Genedata will streamline the whole biopharma lifecycle from process development to late-stage manufacturing. Alessandro Butté, CEO, DataHow AG
BASEL and ZURICH, Switzerland (PRWEB)
September 13, 2022
Genedata and DataHow, both leading innovators for the digital transformation of biopharma R&D, entered a strategic partnership to integrate their platforms to further streamline bioprocess development and manufacturing workflows. The combined solution will directly integrate DataHow’s Digital Twin products, including DataHowLab and SpectraHow, with the Genedata Biopharma Platform so that process development and manufacturing data can be seamlessly exchanged and interpreted. Having experimental data and modelling data available together will streamline digitalization across biopharma process development and manufacturing. This will enable digital tracking of data for every molecule, sample, and process for more efficient process development and integrate state-of-the-art modelling capabilities to better understand and optimize critical attributes of the biopharmaceutical manufacturing process.
DataHow’s platform provides high-performance bioprocess data analysis and predictive modelling tools based on a user-friendly workflow with customized data visualization techniques, hybrid modelling for process understanding and design, and machine-learning to enable self-learning capabilities and knowledge transfer across molecules and scales. Genedata Bioprocess® is a fully integrated biopharma R&D workflow platform, which integrates processes and connects people, data, and laboratory instruments to automate corporate-wide development and manufacturing operations. It supports the entire end-to-end (E2E) process, covering cell line development (CLD), upstream process development (USP), downstream process development (DSP), formulation development (FD), process analytical support, and analytical development (AD). The integration of the platforms results in synergies that further drive harmonization and automation along the full process. Additionally, as part of the collaboration, DataHow and Genedata will expand the integrated platform to other innovation areas in process development and manufacturing, including hybrid model-supported process monitoring and control with Raman Spectroscopy and E2E applications of Digital Twins.
“The development of innovative biotherapeutics, including cell and gene therapies and next-generation vaccines, is based on extremely complex and data-rich R&D processes,” noted Othmar Pfannes, Ph.D., CEO of Genedata. “The Genedata Biopharma Platform enables full automation of experimental workflows due to its flexible data model and open programming interfaces. It also allows emerging technology leaders such as DataHow to integrate their technology platform, minimizing setup and integration work for joint customers and directly creating value out of the generated data. This integration provides the best of both worlds — fully automated high-throughput processes complemented by a comprehensive modelling platform supporting faster and better decision making for process development and manufacturing.”
“Full digitalization of production processes is at the heart of DataHow’s vision. Digitalization will allow users to perform a large majority of tasks related to manufacturing processes in silico and automated. This includes process predictive monitoring, optimization, scenario and deviation analysis, and quality management,” said Alessandro Butté, CEO of DataHow AG. “Both companies share a common vision — providing the biopharma industry with one holistic platform that seamlessly communicates between all involved stakeholders, allowing to manage bioprocess data and knowledge in a comprehensible digital format. Our collaboration with Genedata will streamline the whole biopharma lifecycle from process development to late-stage manufacturing.”
About DataHow
DataHow is a software provider focused on accelerating process development, optimizing manufacturing processes, and increasing robustness by using hybrid modeling solutions. Our software and services are tailored to upstream (cell culture, fermentation, seed train, etc.) and downstream (chromatography, ultrafiltration, diafiltration, etc.) biopharma operations providing the user with essential insights for process development, characterization, and scale-up. Our unique Digital Twin technology allows to handle all process units and their interactions, and to transfer knowledge between scales, projects, and product targets. With our approach we want to support the decision process of process experts, scientists, and operators by leveraging in our technology all available process data and knowledge. DataHow was incorporated in 2017 as a spin-off from ETH Zurich and operates with 45 team members across 3 continents.
http://www.datahow.ch
LinkedIn
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn| Twitter| YouTube
________________________________________
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Share article on social media or email: